Skip to main content
Collection

MHRA guidance on coronavirus (COVID-19)

We are producing guidance and information for industry, healthcare professionals and patients covering the coronavirus (COVID-19) outbreak.

The MHRA is working closely with DHSC and other healthcare partners on COVID-19.

We are prioritising work including:

  • supporting and authorising the development of vaccines
  • clinical trials of new medicines
  • managing the supply of medicines and healthcare products

We also provide information to patients, manufacturers and healthcare professionals through our established information channels and alert systems.

The National Institute for Biological Standards and Control (NIBSC), a centre of the Medicines and Healthcare products Regulatory Agency, also plays a major role in assuring the quality of biological medicines worldwide.

The NIBSC has developed a portfolio of reference and research reagents to support areas of diagnostics, vaccine development and research on COVID-19, and has called upon the scientific community to build standardisation into the pandemic response.

Clinical Practice Research Datalink (CPRD), another agency centre, is making COVID-19 research a top priority by fast-tracking protocols for COVID-19 research. All approved study protocol summaries are published within 72 hours to ensure transparency and to help avoid unnecessary duplication.

The British Pharmacopoeia (BP) has published a statement on its products and services during the outbreak, including some actions for any BP Chemical Reference Substance (BPCRS) customers who are ordering any substances classified as controlled drugs or precursor chemicals. BP has also published a statement on offering free access to supportive pharmacopoeial texts to users at no cost.

The MHRA Inspectorate blog has several posts covering the approach taken on clinical trials and advice on other areas like remote working.

Our guidance on coronavirus (COVID-19)

Regulatory flexibilities

Clinical trials

Vaccines and vaccine safety

Inspections and good practice

Medical devices

Medicines and COVID-19

Fake or unlicensed medicines

News stories